Pharmacist intervention for glycaemic control in the community (the RxING study)

Yazid N Al Hamarneh,1 Theresa Charrois,2 Richard Lewanczuk,3 Ross T Tsuyuki1

ABSTRACT
Objective: To determine the effect of a community pharmacist prescribing intervention on glycaemic control in patients with poorly controlled type 2 diabetes.

Design: Pragmatic, before-after design.

Setting: 12 community pharmacies in Alberta, Canada.

Participants: Type 2 diabetes receiving oral hypoglycaemic medications and with glycated haemoglobin (HbA1c) of 7.5–11%.

Intervention: Pharmacists systematically identified potential candidates by inviting patients with type 2 diabetes to test their HbA1c using validated point-of-care technology. Pharmacists prescribed 10 units of insulin glargine at bedtime, adjusted by increments of 1 unit daily to achieve a morning fasting glucose of ≤5.5 mmol/L. The patients were followed up at 2, 4, 8, 14, 20 and 26 weeks.

Primary outcome: Change in HbA1c from baseline to week 26.

Secondary outcomes: Proportion of patients achieving target HbA1c, changes in oral hypoglycaemic agents, quality of life and patient satisfaction, persistence on insulin glargine, number of insulin dosage adjustments per patient and number of hypoglycaemic episodes.

Results: We screened 365 patients of whom 111 were eligible. Of those, 100 (90%) were enrolled in the study; all 11 patients who did not consent refused to use insulin. Average age was 64 years (SD 10.4), while average diabetes duration was 10.2 years (SD 7). HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9); a change of 1.8% (95% CI 1.4 to 2, p<0.001). Fasting plasma glucose was reduced from 11 (SD 3.3) to 6.9 mmol/L (SD 1.8); a change of 4.1 mmol/L (95% CI of 3.3 to 5, p=0.007). Fifty-one per cent of the patients achieved the target HbA1c of ≤7% at the end of the study.

Conclusions: This is the first completed study of independent prescribing by pharmacists. Our results showed similar improvements in glycaemic control as previous physician-led studies. RxING provides further evidence for the benefit of pharmacist care in diabetes.

Trial registration: clinicaltrials.gov; Identifier: NCT01335763.

INTRODUCTION
Currently, 347 million individuals are living with diabetes worldwide.1 Approximately 90% of them have type 2 diabetes.1 The number of new cases of type 2 diabetes is rapidly increasing mainly because of obesity and an ageing population.2

Because of its chronic nature and the severe complications associated with it, diabetes carries a health and a financial burden on the affected individual and health systems.3 Poorly controlled diabetes puts patients at high risk of suffering from macrovascular and microvascular complications.4

Type 2 diabetes is a progressive disease; it has been reported that 50% of the insulin-producing capacity is lost at the time of diagnosis with an average loss rate of 5% per year afterwards.5 As a result, many patients with type 2 diabetes will eventually require the use of insulin; however, clinicians seem reluctant to start insulin6 despite evidence from studies such as INSIGHT, which demonstrated improved glycaemic control with the addition of insulin glargine to oral hypoglycaemic agents in patients with type 2 diabetes7 as well as guidelines that recommend

1Division of Cardiology, Department of Medicine, EPICORE Centre, University of Alberta, Edmonton, Alberta, Canada
2School of Pharmacy, Curtin University, Perth, Western Australia, Australia
3Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

Correspondence to Ross T Tsuyuki; ross.tsuyuki@ualberta.ca

To cite: Al Hamarneh YN, Charrois T, Lewanczuk R, et al. BMJ Open 2013;3:e003154. doi:10.1136/bmjopen-2013-003154

ARTICLE SUMMARY
Strengths and limitations of the study

- This is the first study of independent prescribing by pharmacists in patients with diabetes and it demonstrates a clinically important improvement in glycaemic control.
- The 26-week follow-up period can be considered relatively short; it is possible that with a longer study more patients may have achieved the target glycated haemoglobin (or fewer if patients discontinued their insulin).
- We did observe several ‘hypoglycaemic-type symptoms’, however we were not able to confirm these as true hypoglycaemia. We also have no frame of reference as patients may have experienced some of these symptoms prior to enrolling in our study. Finally, the number of reported ‘hypoglycaemic-type symptoms’ in this study was consistent with the findings reported in the literature.
starting insulin immediately if the patient’s glycated haemoglobin (HbA1c) is ≥9%.8

Clinicians’ reluctance to initiate insulin due to unfamiliarity with the treatment or using it as a last resort9 plays a major role in influencing the patient’s decision to start insulin treatment regimen. It has been reported that many patients have ‘psychological insulin resistance’ where they are unwilling to take insulin because of certain beliefs that insulin will not be beneficial and in some cases it may even be harmful. Personal experience and messages from different healthcare professionals can also affect the patient’s decisions regarding insulin treatment regimen.6 10

Pharmacists are front line healthcare professionals who see patients with diabetes more frequently than physicians (15 vs 7 times/year)11 and as such, could proactively and systematically identify patients with poorly controlled type 2 diabetes in a broad-based public health approach to chronic disease management.12 Indeed, there is good evidence for the efficacy of pharmacist care in diabetes.13 In community settings, pharmacists have demonstrated that they are capable of identifying poorly controlled patients, educate patients regarding diabetes, medications and self-monitoring of plasma glucose, provide adherence support, identify and resolve diabetes problems and complications and setting goals to reduce the patients’ HbA1c, plasma glucose and improve their quality of life and other comorbidities.4 12–16 Moreover, the scope of practice for pharmacists in Alberta is changing, allowing pharmacists to prescribe medications and order laboratory tests. As such, there is an unprecedented opportunity to identify and improve glycaemic control in patients with type 2 diabetes.

The main aim of the RxING study was to determine the effect of a community pharmacist prescribing intervention on glycaemic control in patients with poorly controlled type 2 diabetes.

METHODS
Study design and setting
RxING was a multicentre pragmatic before–after design trial, which was conducted in 12 community pharmacies in the province of Alberta, Canada.

We chose the before–after design because we had concerns about withholding insulin from this high-risk group. The concerns were based on guidelines recommendations8 and the evidence from studies such as INSIGHT.7

All participating pharmacists, who were either certified diabetes educators (CDE) or preparing to be CDE, received face-to-face training by the study team. The training material was based on the most recent Canadian guidelines and recommendations.7 8 They also received a manual of operations to help them conduct the study.

Study participants
We recruited adults who had physician diagnosed type 2 diabetes for at least 6 months and were receiving one or more oral hypoglycaemic agents, had an HbA1c between 7.5% and 11% and who were willing to sign an informed consent.

We excluded patients who were unwilling to use insulin, previously or currently using insulin (confirmed by the patient’s medication records), had a history of ketoacidosis (confirmed by the patient’s healthcare records), were pregnant, worked night shifts, had renal impairment (serum creatine of ≥124 mmol/L for females or ≥133 mmol/L for males; confirmed by the patient’s healthcare records), were clinically unstable (based on the pharmacist’s judgement), were unwilling or unable to attend follow-up visits or felt to be unlikely to adhere to study procedures due to cognitive limitations (based on the pharmacist’s judgement), severe psychiatric disorders or alcoholism (confirmed by the patient’s healthcare records).

Recruitment
Pharmacists systematically identified potential candidates from within their practice by inviting patients with type 2 diabetes (eg, patients on metformin) to test their HbA1c in the pharmacy using validated point of care technology (DCA Vantage, Siemens, Tarrytown, New York, USA). If the result of the HbA1c test was high (7.5–11%) and the patient met the other inclusion criteria for the study the patient was asked if he/she wanted to participate in the study. After providing written informed consent, the patient was enrolled in the study. If HbA1c was >11% the patient was assessed by the study investigators and the patient was referred to his/her physician.

Intervention
The patient was prescribed 10 units insulin glargine at bedtime and was asked to titrate the dose by 1 unit/day to achieve a fasting plasma glucose (FPG) of ≤5.5 mmol/L.7 17 The intervention also included patient education regarding insulin use, dose titration and self-monitoring. Patients contacted the pharmacist when they reached a FPG of 6 mmol/L. All patients remained on their previously prescribed oral hypoglycaemic agent(s). If the combination with insulin was not approved in Canada, the oral hypoglycaemic agent was discontinued (eg, thiazolidinedione). Adjustments were made at the discretion of the treating pharmacist based on the most recent Canadian guidelines.8 The patient’s family physician received a letter from the pharmacist to inform him/her that the patient was participating in the study.

Follow-up
Patients were followed at 2, 4, 8, 14, 20 and 26 weeks to provide ongoing care, check adherence to the insulin regimen, fasting blood sugars (measured by the patient), insulin dose and titration and adverse events. HbA1c was measured at weeks 14 and 26 using the same technique used at baseline. Family physicians were kept...
informed of patient’s progress and any medication change after each visit.

Outcomes
The primary outcome measure was the change in HbA1c from baseline to week 26. Secondary outcomes included proportion of patients achieving target HbA1c (defined as HbA1c ≤ 7.0%), changes in oral hypoglycaemic agents, quality of life and patient satisfaction using Audit of Diabetes—Dependent Quality of Life (ADDQoL), Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Diabetes Treatment Satisfaction (Change) Questionnaire (DTSQc), persistence on insulin glargine (% still taking insulin at the end of follow-up), number of insulin dosage adjustments per patient, number of hypoglycaemic episodes.

Sample size calculation
With a sample size of 80 patients and the following assumptions, an SD of 1.1 and a two-sided $\alpha$ of 0.05, we calculated 90% power to detect a mean decrease in HbA1c of 0.4%. Since this a pragmatic, practice-based trial, the sample size was inflated to 100 to account for possible losses to follow-up.

Data analysis
The level of significance was set at 0.05. All analyses were performed on intention to treat basis. Missing data

| Table 1 Demographic and clinical characteristics of the patients (N=100) |
|--------------------------|---------------------|
| Characteristic            | Frequency           |
| Gender                   |                     |
| Male                     | 58                  |
| Female                   | 42                  |
| Marital status           |                     |
| Single                   | 8                   |
| Married                  | 77                  |
| Divorced                 | 9                   |
| Widowed                  | 6                   |
| Education                |                     |
| Grade school             | 10                  |
| High school              | 36                  |
| Some postsecondary education | 26              |
| Postsecondary education  | 28                  |
| Employment               |                     |
| Caring for family        | 1                   |
| Working for profit/pay   | 36                  |
| Unemployed/looking for a job | 6              |
| Retired                  | 48                  |
| Other                    | 9                   |
| Self-reported ethnicity  |                     |
| Aboriginal/first nation  | 1                   |
| White                    | 89                  |
| South Asian              | 1                   |
| Oriental                 | 4                   |
| Other                    | 4                   |
| Declined                 | 1                   |
| Medication coverage      |                     |
| Private                  | 29                  |
| Government               | 47                  |
| Out of pocket            | 15                  |
| Private and government   | 7                   |
| Private and out of pocket| 2                   |
| Smoking status           |                     |
| Smoker                   | 22                  |
| Ex-smoker                | 41                  |
| Non-smoker               | 37                  |
| Alcohol consumption      |                     |
| No alcohol               | 43                  |
| Occasional alcohol (eg, 1–3 drinks/week) | 54              |
| 1–2 alcohol drinks/day   | 3                   |
| Self-reported hypertension|                    |
| Yes                      | 63                  |
| No                       | 36                  |
| Unknown                  | 1                   |
| Self-reported high cholesterol|                |
| Yes                      | 64                  |
| No                       | 33                  |
| Unknown                  | 3                   |
were imputed using a last value carried forward strategy. The mean HbA1c between baseline and 26 weeks was compared using paired t test. Secondary outcomes were analysed using paired t tests and basic frequencies. Linear regression was used to adjust for the patients’ demographics and clinical characteristics.

RESULTS
We screened 356 patients with type 2 diabetes; 245 were excluded because they did not meet the HbA1c inclusion criteria. Of the 111 eligible patients, 11 were not enrolled because they refused to use insulin, leaving 100 patients enrolled (figure 1).

The demographic and clinical characteristics of the patients are reported in table 1. Patients’ mean age was 64 years (SD 10.4) and had a diabetes duration of 10.2 years (SD 7). Fifty-eight per cent of the patients were men, 77% were married and 90% reported having at least high school education. Nearly half of the patients (48%) were retired, almost ninety per cent (89%) were white (ethnicity was self-reported) and nearly half (47%) have a government medication coverage. Around one-quarter of the patients (22%) reported that they were smokers and more than half (54%) reported occasional consumption of alcohol (eg, 1–3 drinks/week). Nearly two-thirds of the patients had elevated blood pressure (63%) and elevated cholesterol (64%; hypertension and high cholesterol were self-reported).

All but one patient was taking insulin glargine at the end of the study (he stopped his insulin before the final visit because his plasma glucose readings were ‘good’). At the end of the study the mean insulin glargine dose was 31.1 units (SD 18.4) with a mean of 21.1 dose adjustments (SD 18.8) per patient.

HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9) at 26 weeks, a change of 1.8% (95% CI 1.4 to 2, p<0.001; figure 2), whereas FPG was reduced from 11 mmol/L (SD 3.3) at baseline to 6.9 mmol/L (SD 1.8) at 26 weeks, a change of 4.1 mmol/L (95% CI of 3.3 to 5, p=0.007; figure 3).

Fifty-one per cent of the patients achieved the target HbA1c of ≤7% at the end of the study. At baseline, two-thirds (66%) of the patients were taking two or more medications (table 2), the most widely used combination was metformin and gliclazide, followed by metformin and glyburide and metformin and repaglinide. Nearly half of the patients (48%) had their oral hypoglycaemic regimen altered (table 3); the most frequent alterations were stopping sulfonylurea (46%) followed by initiating meglitinides (23%), stopping metformin (21%) and stopping thiazolidinedione and dipeptidyl peptidase 4 inhibitors (19%). Those alterations were made by the pharmacists who then informed the patients’ family physicians.

Only 40% of the patients returned quality-of-life and treatment satisfaction questionnaires. Of those, only 30 questionnaires were analysable. Quality of life and treatment satisfaction have improved by 0.2 and 3.5, respectively among the patients who returned the questionnaires.

| Number of oral agents | Frequency | Mean HbA1c (SD) |
|-----------------------|-----------|----------------|
| 1                     | 34        | 8.7 (0.9)      |
| 2                     | 56        | 9.1 (0.9)      |
| 3                     | 7         | 9.8 (1.6)      |
| 4                     | 3         | 8.7 (0.7)      |
Body mass index was 31.6 (SD 6.3) at baseline and 32.6 (SD 6.3) at the end of follow-up (p=0.29) and waist circumference was 106 cm (SD 13.8) at baseline and 107.4 cm (SD 12.9) at the end of follow-up (p=0.5).

‘Hypoglycaemic-type’ symptoms were reported by 54 patients. Only two of these episodes required medical attention (one caused a visit to the family physician while the other required a visit to the emergency department without an overnight stay). We were neither able to confirm whether these episodes were true hypoglycaemia, through blood glucose measurements, nor did we have baseline information on such symptoms.

**DISCUSSION**

We found that a community pharmacist prescribing intervention in patients with poorly controlled type 2 diabetes improved patients’ HbA1c by an absolute value of 1.8% (95% CI 1.4 to 2, p<0.001) and FPG by 4.1 mmol/L (95% CI of 3.3 to 5, p=0.007). This is the first study of independent prescribing by pharmacists in patients with diabetes and represents a clinically important improvement in glycaemic control.

Our findings are consistent with the findings of Gerstein et al. and Harris et al. who compared the effect of adding insulin glargine to the oral hypoglycaemic regimen versus the conventional therapy where oral hypoglycaemic agent doses were adjusted. They reported better glycaemic control in the insulin glargine group after 26 weeks of follow-up. Our findings are also consistent with the findings of Wubben and Vivian who conducted a systematic review to assess the effectiveness of pharmacist intervention in patients with diabetes in outpatient settings. They reported additional HbA1c reduction (when compared to usual care) of 0.5% when pharmacists did not have prescribing authority and 1% when pharmacists had prescribing authority (collaborative prescribing in this case).

It has been reported in the literature that the adherence rates to the insulin regimen are unsatisfactory; however, in our study, 99% of the patients were adherent to their treatment regimen for 6 months. This can be explained by the intensive intervention provided by the pharmacist and the relatively short duration of the study.

This study is not without limitations. The 26-week follow-up period can be considered relatively short; it is possible that with a longer study more patients may have achieved the target HbA1c (or fewer if patients discontinued their insulin). Patients who were unwilling to use insulin were excluded from the study; however, patients’ willingness to use insulin was high in our pilot study and also during the screening process. The proactive and systematic approach that we used in this study also helped in identifying patients who could benefit from insulin. We acknowledge that adding insulin to the oral hypoglycaemic agent(s) regimen is one of the options that are available to improve glycaemic control; however, this choice was based on the insulin’s efficacy and safety profile. The response rate to quality-of-life and treatment satisfaction questionnaires was low; however, the improvements in quality of life and treatment satisfactions are consistent with the findings of Gerstein et al. who reported improvements in treatment satisfaction in the insulin glargine group. We also received unsolicited comments from different patients highlighting their pleasure and satisfaction with treatment and its impact on their daily activities.

We did observe several ‘hypoglycaemic-like’ symptoms; however, we were not able to confirm these as true hypoglycaemia. We also have no frame of reference as patients may have experienced some of these symptoms prior to enrolling in our study. Finally, the number of reported ‘hypoglycaemic-type symptoms’ in this study was consistent with the findings of a meta-analysis of more than 1100 diabetes patients who were using insulin glargine.

Our findings take the evidence for the benefits of pharmacist care in diabetes one step further. That prescribing insulin improves glycaemic control in itself is perhaps not surprising; what is important is that pharmacists can systematically identify patients with poor glycaemic control, educate and support patients to achieve better outcomes. Since pharmacists see patients with diabetes frequently, this can be an attractive approach.

**Acknowledgements**

The authors would like to acknowledge the participation of the following pharmacists and pharmacies in making this study possible: Rick Siemens (London Drugs, Lethbridge), Darsey Milford (Turtle Mountain Pharmacy, Bellevue), Rita Bowron, Rami Chowaniec, Nader Hammoud, Carol Wei, Sheilah Kostecki (Safeway Pharmacy, Edmonton and Calgary), Anita Brown (Shoppers Drug Mart, Okotoks), Jannelle Fox, Tony Nickonchuck (Walmart Pharmacy Cold Lake and Peace River), Rita Lyster (Rita’s Apothecary and Home Healthcare, Barrhead) and Anita and Warren Dobson (Medicine Shoppe, Calgary).

**Contributors**

All the authors have made substantial contributions to the article. YNAH had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. RTT and TC were involved in study concept and design. RTT and YNAH were involved in acquisition, analysis, interpretation of the data, statistical analysis and drafting of the article. RTT, RL, TC and YNAH contributed in critical revision of the article for important intellectual content and provided administrative, technical and material support. RTT and RL were involved in study supervision.

**Funding**

This work was supported by unrestricted investigator-initiated funding provided by Sanofi Canada and the testing equipments were provided by ManthaMed.

---

**Table 3** Oral hypoglycaemic use at baseline and the end of the study

| Medication       | Baseline (N=100) | 26 Weeks (N=93) |
|------------------|------------------|-----------------|
| Metformin        | 88               | 78              |
| Sulfonylurea     | 54               | 32              |
| Meglitinides     | 18               | 29              |
| Dipeptidyl peptide 4 | 12           | 3               |
| Thiazolidinedione | 9                | 0               |

---

1. Gerstein et al.
2. Harris et al.
3. Wubben and Vivian.
4. Rick Siemens.
5. Darsey Milford.
6. Rita Bowron.
7. Nader Hammoud.
8. Carol Wei.
9. Sheilah Kostecki.
10. Anita Brown.
11. Jannelle Fox.
12. Tony Nickonchuck.
13. Walmart Pharmacy Cold Lake.
14. Peace River.
15. Rita’s Apothecary.
16. Home Healthcare.
17. Barrhead.
18. Anita Brown.
19. Warren Dobson.
20. Medicine Shoppe.
21. YNAH.
22. RTT.
23. TC.
24. YNAH.
Competing interests None.

Patient consent Obtained.

Ethics approval Health Research Ethics Board of the University of Alberta.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

1. World Health Organization. Diabetes. 2012. http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed Feb 2013).
2. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence and mortality in Ontario, Canada 1995–2005: a population based study. Lancet 2007;369:750–6.
3. Al Hamarneh YN, Rosenthal M, Tsuyuki RT. Glycemic control in community-dwelling patients with type 2 diabetes. Can Pharm J 2012;2:68–9 e1.
4. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999;7:139–53.
5. Polonsky WH, Jackson RA. What’s so tough about taking insulin? Clin Diabetes 2004;22:147–50.
6. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT study. Diabet Med 2006;23:736–42.
7. Canadian Diabetes Association. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:1–201.
8. Harris S, Yale JF, Dempsey E, et al. Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: Lessons for family practice from Canadian INSIGHT trial. Can Fam Physician 2008;54:550–8.
9. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005;28:2543–5.
10. Shiu JR, Simpson SH, Johnson JA, et al. Quantifying opportunities to affect diabetes management in the community. Can Fam J 2006;139:37–5.
11. O’Donovan D, Byrne S, Sahm L. The role of pharmacists in control and management of type 2 diabetes mellitus; a review of the literature. J Diabetes 2011;1:5–21.
12. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacoepidemiology 2008;28:421–36.
13. Armour CL, Taylor SJ, Hourihm F, et al. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc 2004;44:455–66.
14. Formos JA, Andres NF, Andres JC, et al. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci 2006;28:65–72.
15. Krass I, Armour CL, Mitchell B, et al. The pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med 2007;24:677–83.
16. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007;1:540–8.
17. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life and adherence. Clin Med Res 2008;6:54–67.
18. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine in type 2 diabetes. Diabetes Care 2005;28:950–5.
Correction

Al Hamarneh YN, Charrois T, Lewanczuk R, et al. Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open 2013;3:e003154. Figure 2 of this article was published with incorrect text in the change box. The correct text is: $\Delta=1.8\%$; $p<0.001$ (95% CI 1.4–2). We apologise for this error.

BMJ Open 2013;3:e003154corr1. doi:10.1136/bmjopen-2013-003154corr1